Table 2.

Input parameters in the partitioned survival model

	Baseline value ($)	Range ($)	Distribution	Reference
Durvalumab	7,866.6/ 1,500 mg	5,899.95–9,833.25	lognormal	[20]
Atezolizumab	4,755/1,200 mg	3,566.25–5,943.75	lognormal	[20]
Pembrolizumab	2,612.83/100 mg	1,959.69–3,266.11	lognormal	[27]
Nivolumab	665/40 mg	498.75–831.25	lognormal	[20]
Ipilimumab	81.2/mg	60.9–101.5	lognormal	[20]
Sintilimab	157.5/100 mg	118.13–196.88	lognormal	[28]
Camrelizumab	426.9/200 mg	320.2–533.7	lognormal	[29, 30]
Tislelizumab	317.89/100 mg	238.42–397.36	lognormal	[31]
Bevacizumab	262.5/100 mg	196.88–328.13	lognormal	[32]
Tremelimumaba	81.2/mg	60.9–101.5	lognormal	-
Carboplatin	0.16/mg	0.12–0.21	lognormal	[27]
Pemetrexed	131.24/100 mg	98.43–164.05	lognormal	[32]
Docetaxel	189.57/200 mg	142.18–236.96	lognormal	[33]
Cost of medical service of immunotherapy per cycle	8.20	6.15–10.25	lognormal	[27]
Cost of medical service of chemotherapy per cycle	45.97	34.48–57.47	lognormal	[27]
Follow-up cost per cycle	58.53	43.90–73.17	lognormal	[27, 34]
Utility for PFS	0.804	0.683–0.925	beta	[35]
Utility for PD	0.321	0.273–0.369	beta	[35]
Utility for death	0	0	-	-
Discount rate	5%	0–8%	-	[25]

^aThe price of tremelimumab was assumed to be identical to that of ipilimumab, because tremelimumab was not approved to enter into the market